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Aptamers are a short polymer of oligonucleotides (natural or modified) that can 
bind to its cognate target (small molecules to large macromolecules like proteins, 
cells, microorganisms etc.) with high affinity and selectivity. They can fold into 
unique secondary and tertiary conformation in solution (pH, ionic concentration) 
and bind to their targets in a specific manner (binding constants in sub-nano to pico 
molar range). They rival the monoclonal antibodies and other specific biological 
ligands with respect to affinity, stability, robustness, non-immunogenicity and facile 
to synthesis. Nucleic acid aptamers are selected from an oligonucleotide library by 
an iterative process called SELEX (Systematic Evolution of Ligands by Exponential 
Enrichment Analysis). These aptamers are compatible to any kind of chemical modi-
fication, conjugation and functionalization. Briefly, this chapter discusses about the 
diagnostic and therapeutic application of aptamers.
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1. Introduction
Aptamers (Latin word aptus means ‘to fit’ and Greek meros meaning ‘part’) 
are single stranded oligonucleotides, which act as synthetic ligands for its 
cognate target molecules. [1, 2] These molecules show high target specific-
ity, selectivity and affinity, which resemble ‘monoclonal antibody’. Similar to 
antibodies, aptamers also have immense potential to interact with their targets 
by structural recognition and thus they are termed as ‘chemical antibodies’. [3] 
Different conformations allow aptamers to bind specifically with their target 
by ‘lock and key’ model. This hypothesis of binding mechanism is driven by the 
secondary and tertiary structure of aptamers in-bound state with their targets. 
Adopting various structures like hairpin loops, bulges, stem-loop, quartets, 
G-quadruplex, pseudo knots, aptamers can fit into the binding region of the 
target. [4] Intra and inter molecular interactions like hydrogen bonding, Vander 
Waals force, hydrophobic interaction, electrostatic forces play major crucial role 
in aptamer-target interaction. [5] However, the aptamers are primarily synthetic 
molecules and naturally occurring ribozymes are single stranded RNA molecules, 
which also have similar recognition domain acting in a similar manner. [6, 7] 
Aptamers are capable of forming various stable three-dimensional structures in 
physiological solution. The folding process in solution and the ligand-induced 
conformational switch is strongly dependent on the presence of divalent cations 
(magnesium, potassium etc.). [8] There are plethora of computer algorithms 
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enable sequence based modeling of secondary structure of the oligonucleotide 
aptamers which actually strengthen the predictability of strongest binders with 
lowest free energy. [9, 10] Aptamers fold into tertiary conformations and bind 
to their targets through shape complementarity at the aptamer-target interface. 
[11] An aptamer binds to a protein can modulate protein functions by interfering 
with protein interaction with natural partners. Similar to antibodies, aptamers 
can enter to specific target cells via receptor-mediated endocytosis upon binding 
to cell surface ligands. [12] Importantly, aptamers can penetrate into tumor cores 
much more efficiently than antibodies due to their ~20–25-fold smaller sizes 
compared with full sized monoclonal antibodies. [13, 14]
Monoclonal Antibody Aptamer
Stability: Monoclonal antibodies require 
refrigeration to avoid denaturation. Limited 
shelf life. [15]
Stability: Aptamers do not require refrigeration. 
Indefinite shelf life. [16]
Immunogenicity: They can cause 
immunogenic response. [17]
Immunogenicity: Aptamers are non-immunogenic. [18]
Production: laborious, expensive, high batch-
to-batch variation.
Production: simpler and controlled chemical reactions, 
little to no variation, automated, chemical synthesis, no 
contamination.
Size: Larger in size, they can resist filtration by 
the kidneys, long half-lives. However, their size 
prevents access to smaller areas. [19]
Size: Aptamers are small molecules. They are especially 
subject to kidney filtration, resulting in short half-lives. 
Compared to antibodies, aptamers can bind to smaller 
targets. [20]
Ability to modification: Antibodies cannot 
accommodate conjugates without negative 
consequences such as reduced activity.
Ability to modification: Easy to modify, modifications 
can also be incorporated during synthesis to prevent 
kidney filtration. [21]
Table 1. 
Comparison between Monoclonal antibody vs. Aptamer:
Figure 1. 
Publication trend for Search strings: “Aptamers as diagnostics” and “Aptamers as therapeutics” (Source: 
Scopus).
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Compared to antibodies, aptamers can be produced using cell-free chemi-
cal synthesis and are therefore less expensive for large-scale manufacture. 
Aptamers exhibit extremely low variability between batches and have better 
controlled post-production modification, they are minimally immunogenic, and 
are small in size. (Table 1) The rapidly growing aptamer industry was predicted 
to reach US $244.93 million by 2020. [22] Presently more than 40 companies 
are actively engaged in diagnostics and therapeutics research to commercialize 
these “magic bullets” globally (EU countries, Asia, USA, UK etc.). [23] The 
largest company is “SomaLogic” (company based on SOMAmer- a patented 
“Slow Off-rate Modified Aptamer) founded by Prof. Larry Gold at Colorado, 
USA. Since the advent of aptamers scientists and researchers exploit different 
applications of aptamers that reflects the following trends in the publications. 
(Figures 1 and 2).
2. Basics of SELEX screening process
Back in 1990, two individual groups Prof. Larry Gold and Craig Tuerk from 
University of Boulder, USA and Prof. Jack Szostak and his student A.D. Ellington 
from Havard University, USA discovered the evolution process to obtain the oligo-
nucleotide binders and they coined the term ‘Aptamer’ and the process as ‘SELEX’. 
[24, 25] Systematic Evolution of Ligands by Exponential Enrichment (SELEX) is 
a common screening process by which aptamers can be selected from an aptamer 
library which consist of 1024–25 number of various sequences. The method attempts 
to isolate an aptamer of interest from a pool of randomized library by an iterative 
cycle of incubation with the target, partitioning and amplification, until the pool of 
aptamers enriched enough to fit with the target. The SELEX procedure iterates over 
five basic steps- incubation of aptamer pools with the target, binding, partitioning 
and washing (to get rid of non-binders which are loosely bound with the target), 
then elution of positive target-bound aptamers and amplification of enriched pools. 
Traditionally, the positive pool eluted from last round is being analysed, and high-
throughput sequencing is performed.
An array of different RNA and DNA aptamers were isolated against a vast array 
of targets: ions, [26] low molecular weight metabolites, [27, 28] proteins, [29–31] 
sugar moieties [32] lipids, [33] and even whole cells. [34, 35]
Figure 2. 
Publication trend for Search strings: “Aptamers as theranostics” (Source: Scopus).
Theranostics - An Old Concept in New Clothing
4
3. Library selection
To select highly selective, specific aptamers, design of the initial aptamer library 
is the first and foremost step. In case of determination of the length of the random 
region researchers should consider the sequence space and structural diversity. The 
complexity of the initial aptamer library depends on the length of the random win-
dow of the aptamer library (If the random window is 40 and if we consider DNA 
aptamer library, so the complexity of the library is: 4^40 that equals to 1024–25). [36]
Special libraries would consist of specifically designed flanking sequences 
directing the aptamers to form a specific secondary structure, or include modified 
nucleotides. In capture SELEX, there is unique docking sequence (12–14 nucleotides 
long) which enables the library in such a way, that highly sensitive aptamers can 
be fished out against small molecules. [37, 38] The extended genetic alphabets or 
combination of artificial xeno nucleic acids (XNA) greatly broaden the diversity 
of sequences and can influence the properties of the aptamers, such as their in vivo 
stability or nuclease resistance. [39–42] Modified nucleotides can be introduced 
either during the library synthesis or in the post-selection optimization.
In a review article, Maria et al. summarized all key features of designing nucleic 
acid libraries for SELEX like nature, composition of the library (RNA, DNA or 
modified nucleotides), the length of a randomized region and the presence of fixed 
sequences. Different randomization strategies and computer algorithms of library 
designs were also discussed. [43]
4. Various SELEX processes
Specific aptamers are screened by the iterative processs of SELEX from a highly 
diverse pool of oligonucleotides. [44–46] After the incubation of the random aptamer 
pool with the target followed by the removal of non- binding aptamers, the bound 
aptamer species are recovered. These recovered nucleic acid sequences are amplified 
with PCR (in the case of DNA aptamer) or RT-PCR (for RNA aptamers). In addition to 
selection against a purified target molecule, SELEX process can be performed against 
live bacterial cells and even in mammalian cell lines to isolate cancer cell specific 
aptamers and furthermore it can lead to the identification of novel biomarkers. [47, 48]
Figure 3. 
Typical schema of Cross-over SELEX process.
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A giant advancement of SELEX technology has been made since its discovery 
in 1990. Conventional SELEX is a well-established and effective method but due to 
its immense time- and labor-consumption, continuous improvement of alternative 
methods for aptamer selection has been inevitable.
High throughput SELEX (HT-SELEX), Functional screening (Microfludics or 
Flow cytometry based SELEX), Cross-over SELEX (where the target is alternatively 
changing from proteins and cells), (Figure 3) in-vivo SELEX, Spiegelmers selec-
tion, de-convolution SELEX are few examples of modern-era screening strategy of 
aptamers. [49] Cutting-edge functional screening process, the chemical modifica-
tions, Next-generation sequencing (NGS technology) enable SELEX more efficient, 
cost-effective and considerably less time-consuming.
5. Modifications of naturally occuring aptamers
DNA is the backbone of central dogma of our life cycle. Moreover, any form of 
nucleic acids play a crucial role in our genetic codon. DNA/RNA is an essential bio-
macromolecule consist of nucleotide bases such as adenine (A), thymine (T), uracil 
(U), guanine (G), cytosine (C).
There are various types of modifications (nucleotide base modifications, phos-
phate backbone modifications, peptide mimic oligonucleotides PNA etc.) available 
which can prevent aptamers from nuclease degradation. Locked nucleic acid (LNA) 
is one among them where 2′-oxygen has been linked to the 4′-carbon of the ribose 
sugar by a methylene bridge, thus completely locking the sugar into a 3′-endo con-
formation. LNAs increase the thermodynamic stability, binding affinity, and enable 
the oligonucleotides to prevent serum degradation. [50–52] These modifications 
enable the aptamers for biological applications.
Compared to LNAs, the unlocked nucleic acid (UNA) is an acyclic ribose deriva-
tive that has increased flexibility. UNAs do not consist the C2’-C3’ bond, which 
confers the flexibility observed in this modified nucleotide. [53] LNAs increase 
the melting temperature of the nucleotide by 1–10°C per LNA insertion but UNAs 
reduce the melting temperature by 5–10°C retaining the nuclear resistance. In case 
of, Peptide nucleic acid (PNA) in which sugar-phosphate backbone is modified 
by short stretch of N-(2-aminoethyl)-glycine units connected by peptide bonds, 
enhances biostability of the modified candidates. [54]
5.1 Aptamers in Drug development pipeline
Aptamers have been incorporated in drug development pipeline as they have 
the capacity to block the downstream signalling (phosphorylation of kinases etc.) 
of different biomolecules. They can play an important role to regulate various cel-
lular crosstalks. To screen therapeutic aptamers either DNA aptamers or 2′-fluoro 
modified RNA, a combination of 2′-fluoro pyrimidines and 2′-hydroxyl purines 
(fYrR) are of major interest. fYrR is the “nuclease stable RNA” and can be easily 
generated by Y639F modified T7 RNA polymerase. Fovista, an anti-platelet derived 
growth factor (PDGF) aptamer, was previously DNA aptamer but later modified 
to augment the stability with the addition of backbone modifications. [55] As with 
the 2′-fluoro modification, the 2’-OMe modifications adopt a C3’-endo conforma-
tion. US FDA approved the first aptamer (Macugen®, pegaptanib sodium) in 
2004 against vascular endothelial growth factor for the treatment of age-related 
macular degeneration. [56] This aptamer was modified with 2′-fluoro-pyrimidines 
and 2’-O-methyl-purines. The stability of the small aptamer was a critical factor  
but later which can be circumvented with a 3′-cap and a polyethylene glycol 
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molecule, the half-life of Macugen® was extended to 131 hours at max. [57, 58] 
Anti-vascular endothelial growth factor (VEGF 165) aptamer Macugen, and an 
anti-Factor IXa aptamer REG1 were both selected from fYrR libraries, and sub-
sequently 2′-O-methyl nucleosides have been incorporated in order to increase 
serum stability. [57]
There is a plethora of polymerase enzymes like KOD, Pwo, Phusion, Superscript 
III, vent (exo-), T7 polymerase have all been shown to be capable of incorporating 
modified triphosphates into DNA and RNA strands, which open up a new oppor-
tunities in aptamer selection strategies. [59] The use of Pfx DNA polymerase allows 
amplification of Ds-Px base pair in Ex-SELEX protocol where extended genetic 
alphabets were included in complexity of nucleic acid library. [60]
Several limitations of aptamers should be considered in the process of in-vivo 
applications of nucleic acid aptamers. Being polynucleotides, nucleic acid aptam-
ers are naturally susceptible to enzymes degradation by exo and/or endo-nucleases, 
leading to a reduced in vivo circulatory half-life. This drawback can be alleviated by 
side chain chemical modifications to aptamers, incorporating unnatural nucleotide 
bases (locked and unlocked nucleic acids) and capping the aptamer ends, thus 
minimizing the susceptibility to endonuclease and exonuclease attack. [50, 51] 
Short blood residence time is another challenge with in vivo aptamer applications, 
which is due to fast removal of aptamer from the circulation by renal filtration as 
most aptamers have a size smaller than the renal filtration threshold of 40 kDa. 
[31] To achieve desired serum half-life, aptamers can be engineered by conjuga-
tion with a terminal polyethylene glycol (PEG), although this may compromise 
the extent of tumor penetration [61]. In some cases, post-SELEX modifications 
following the selection of aptamers may alter the 3-D structure of the aptamers, 
leading to the lost or altered binding affinity and specificity. Such problems can 
be prevented by using random aptamer pools containing modified nucleotides 
during the SELEX process. [62, 63] In addition, the ability of aptamers to interact 
with cells may decrease due to repulsion of nucleic acids by negatively-charged cell 
membranes. This can be refuted by increasing the binding affinity and specific-
ity of aptamers toward their cell surface receptors to trigger receptor-mediated 
endocytosis.
In the field of oncology, two aptamers, namely, AS1411 and NOX-A12, have 
entered clinical trials. [45, 64] AS1411 (formerly ARGO100; Antisoma) is a guanine 
quadruplex aptamer obtained from a guanine-rich oligonucleotide library in the 
anti-proliferation screen, which is not a typical SELEX process. [65] The guanine 
quadruplex structure benefits AS1411 because it is resistant to nuclease degrada-
tion and enhances cell uptake. In in-vitro validations, AS1411 inhibits more than 80 
types of cancer cell lines. In addition, the target of AS1411 has been verified to be 
nucleolin, and the relevant mechanism and specificity against cancer cells have also 
been described. In preclinical tests, AS1411 shows efficacy toward xenograft mod-
els, including non-small cell lung, renal, and breast cancers. It entered clinical trials 
in 2003 and passed phase II trials for acute myeloid leukemia. A subsequent phase 
II trial for renal cell carcinoma started in 2008 (clinical trial ID NCT00740441). 
[66] NOXA12 (Olaptesed pegol; Noxxon) is an L-form RNA aptamer known as 
Spiegelmer and is used for cancer therapy. NOX-A12 can bind to its target chemo-
kine CXCL-12 and blocks its interaction with its receptor. [67] This disrupts the 
tissue gradient of CXCL-12 and reduces the cancer cell homing that might lead to 
tumor metastasis and drug resistance. [68] Currently, phase II clinical trials for 
NOX-A12 are underway for the treatment of chronic lymphocytic leukemia and 
refractory multiple myeloma (clinical trial IDs NCT01486797 and NCT01521533). 
[67] Aptamer based cancer therapeutics have immense potential for precise and less 
toxic treatment for cancer patients. [46]
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6. Aptamers as diagnostic agents
Aptamers can be used in-vitro and in-vivo as well. [69] In terms of in vivo 
diagnostics, ‘escort’ aptamers can be implied as vehicles for a detectable molecules, 
such as radionuclides, fluorophores etc. [70–72] The development of new agents 
like radio-pharmaceuticals is challenging. There are some important factors such 
as efficiency of the radiolabeling process, specific activity (radioactivity per moles 
e.g. Ci/μmol), chemical purity, radiochemical and chemical stability and shelf life 
of the final product. [73] Mostly, radiolabeling strategies for aptamers are similar as 
for proteins, or antibodies. Aptamers can be easily chemically modified at its 5′ or 3′ 
end with a desired functional group for radiolabeling (Figure 4).
Radiohalogens (fluorine-18, bromine-76, iodine-125 etc.) are the most com-
monly used for radiolabelling oloigonuclotides which are often accompanied with 
prosthetic groups. Recently, click-chemistry for radiofluorination was demonstrated 
on antisense oligonucleotides and siRNAs. [74, 75] Another report used photocon-
jugation as strategy for the radiofluorination of an aptamer. [76] Oligonucleotides 
have also been radiolabeled with the radiohalogens such as bromine-76 for PET 
imaging and iodine-123 for SPECT (Single photon emission computed tomography) 
imaging. In addition, iodine-125 has been used to radiolabel antisense oligonucle-
otides, aptamers and spiegelmers for theranostic applications. Due to the harsh and 
non-aqueous reaction conditions usually needed to radiolabel prosthetic groups, it 
is performed before the conjugation process to the oligonucleotide. [73]
Figure 4. 
Aptamers modified with radiolabelled molecules for disase diagnosis (Figure adapted from Gijs et al) [73].
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Till date, a plethora of aptamers have been modified or labelled with radioactive 
molecules. Aptamers against several important biomarkers like PMSA, Tenascin 
C, thrombin, MUC1 were already exploited for radiolabelling. Aptamer-based 
radiopharmaceuticals were primarily developed for imaging and therapy of cancer 
diseases, metabolic disorders and others. The aptamers are mainly radiolabeled 
with technetium-99 m for SPECT (Single photon emission computed tomography), 
PET (Positron emission tomography) imaging. Very few aptamers were published 
related to PET imaging, and there is only one study of radiolabeled aptamers for 
therapy by Bandekar et al. [77] Other radiolabeled aptamers have only been tested 
for preclinical applications or in the course of preclinical assesement.
Molecular nuclear imaging technique is a diagnostic process of non-invasive 
visualization of any disease in-vivo at molecular level with high precision. For 
nuclear imaging, the probes used for radiolabelling has to be modified accordingly. 
Aptamers are the most promising candidates with versatile modification capibility, 
can be easily engineered for various imaging and other diagnostic purposes.
The first radiolabeled aptamer for nuclear imaging was discovered by Charlton 
et al. A DNA aptamer, NX21909, was selected against human neutrophil elastase, an 
enzyme which is secreted by neutrophils and macrophages during inflammation to 
kill pathogens. [78]
Aptamer TTA1, an RNA aptamer targeting the extracellular matrix protein 
tenascin C (TN-C), was the first radiolabeled aptamer which was used as molecular 
cancer imaging agent. Aptamer TTA1 was generated by a cross-over SELEX involv-
ing the purified recombinant TN-C protein and TN-C-positive U251 glioblastoma 
cells. [79, 80]
7. Lightup aptasensors for diagnostic applications
There are a unique group of aptamers (generally RNA aptamers) which can bind 
specifically with their cognate fluorogen molecules like DFHBI, thiazole orange, 
thioflavin T etc. [49, 81, 82] The non-fluorescent moelcules (native unbound 
state) become fluorescent (bound state) after binding to the aptamers and these 
“light-up” aptamers generate fluorescence signal. In the omni-presence of target 
molecules (small pre-miRNAs) and malachite green (fluorogen) light up aptasen-
sors ‘malaswitch’ exhibit fluorescence enhancement. [83] We can engineer the 
small-molecule specific aptamers (like aptamers for some pesticides, toxins, small 
metaboltes) in such a way, that combined with light-up aptamers, they can generate 
a detectable signal. Light up aptasensors are promising alternative biosensor for 
label free sensitive detection of small molecules. [84]
8. Future perspectives
With more focus on in vivo studies for potential clinical applications, aptam-
ers can be developed in combination with DNA nanostructures, nanomaterial, or 
microfluidic devices as diagnostic probes or therapeutic agents for cancers, infectious 
diseases, genetic, metabolic, neurological disorders, lifestyle diseases and several 
others. The use of aptamers as targeting agents in drug delivery can also be explored. 
Aptamers might be exploited to develop portable, low-cost and robust diagnostic 
kit using simple devices for real-time and on-site POC (point-of-care) detection 
and monitoring, instead of the laborious and time-consuming diagnostic tests 
currently available only in clinical labs. Regarding therapeutics approach, there is 
still untapped potential in the combination of the target recognition and strong 
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binding property of aptamers with exquisitely designed nanomaterials. It can be 
used as an effective alternative drug delivery platform. Variety of materials such 
as liposomes, polymer vesicles and silica nanoparticles, combined with DNA/RNA 
aptamers, has shown feasibility for use in in vivo targeted drug delivery. [85, 86] 
The integration of diagnostic capability with therapeutic interventions termed, as 
“Theranostics” is critical to address the challenges of disease heterogeneity and 
adaptation. Although aptamers have immense potential as theranostic agents, 
tailor-made modifications, validation of experiments need to be executed before 
aptamer-based drug delivery can reach clinical trials and eventually the patient 
management system.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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